Asian Pac J Cancer Prev 2019 Mar 26;20(3):893-896. Epub 2019 Mar 26.
Department of Histopathology, Liaquat National Hospital and Medical College, Karachi, Pakistan. Email:
Background: Quantitative immunohistochemical expression of Androgen receptor (AR) has not been evaluated
as a prognostic biomarker of prostate cancer in our population, therefore in the current study we aimed to evaluate
the association of AR expression in prostatic acinar adenocarcinoma with various prognostic parameters like tumor
quantification, Gleason score, WHO grade group and perineural invasion. Methods: Total 121 cases of biopsy proven
prostatic acinar adenocarcinoma were selected from records of pathology department archives from January 2013 till
December 2017. Hematoxylin and eosin stained slides and paraffin blocks were retrieved and new sections were cut
where necessary. Slides of all cases were reviewed by two senior histopathologists and pathologic characteristics like
Gleason score, WHO grade, tumor quantification, perineural and lymphovascular invasion were evaluated. Androgen
receptor immunohistochemistry was applied on all cases. Results: Low AR expression was noted in 53 cases (43.8%)
while high AR expression was seen in 68 cases (56.2%). Significant association of AR expression was noted with total
Gleason score, WHO grade and percentage of tissue involvement (tumor quantification). Univariate binary logistic
regression showed patients with low Gleason scores (scores 6,7 or 8) and low WHO grade (grade 1, 2 or 3) were less
likely to express high AR expression in comparison to high Gleason score (score 9) and high WHO grade group
(grade 5) respectively. Similarly, cases with low tissue involvement by carcinoma (<50%) were less likely to show
high AR expression in comparison to cases with >50% tissue involvement by carcinoma. Conclusion: Significant
association of AR expression was noted with total Gleason score, WHO grade and percentage of tissue involvement
(tumor quantification) which are among the most important markers of tumor progression; therefore we suggest that AR
expression should be performed in patients with prostatic adenocarcinoma for prognostic stratification of the patients.
We have submitted your request - we will update you on status within the next 48 hours.
Sign up for further access to Scientific Publications and Authors!
What are PubFacts Points?
PubFacts points are rewards to PubFacts members, which allow you to better promote your profile and articles throughout PubFacts.com
How do I earn PubFacts Points?
Each member is given 50 PubFacts points upon signing up. You can earn additional points by completing 100% of your profile, creating and participating in discussions, and sharing other members research.
What can I do with PubFacts Points?
Currently, you can use PubFacts Points to promote and increase readership of your articles.